国产传媒

Zuzana is an addictologist, researcher, and PhD student working at the intersection of addiction treatment, psychedelic research, and healthcare implementation in the Czech Republic. She is a Research Associate at the Psychedelic Research Centre of the National Institute of Mental Health in Prague, where she has worked as a clinical coordinator of multiple RCTs and as an assisting therapist in clinical trials involving ketamine and psilocybin.

Her work focuses particularly on the integration of psychedelic-assisted psychotherapy into addiction care, including clinical service development, multidisciplinary education, professional role definition, and policy translation. She is also a co-founder of the ketamine clinic CIT Klinika Podané ruce and advises on psychedelic research and services at Spole?nost Podané ruce, an NGO with multiple services accross Czech Republic with primary focus on SUDs and addictive behaviour.

Zuzana is currently working on Psychedelics at the intersection of Health and Social care, an EU co-funded innovation project that includes an observational study of ketamine-assisted psychotherapy and broader activities in advocacy, education, and system development. Her wider interests include harm reduction, equitable access to psychedelic-assisted treatment, and the development of safe, multidisciplinary models of care for people with substance use disorders.

The Czech Republic is currently facing a new phase in the integration of psychedelic-assisted treatment into healthcare. This talk will introduce "Psychedelics at the intersection of Health and Social care", an EU co-funded innovation project that combines research, clinical service development, advocacy, education, and regulatory work.

The project includes an observational study of ketamine-assisted psychotherapy with three ketamine-assisted sessions for 50 patients, approximately half of whom are expected to be people with substance use disorders. This raises important clinical and systemic questions: how to safely include addiction populations, how to define preparation and integration, how to train multidisciplinary teams, and how to build treatment pathways that extend beyond substance administration.

The talk will also discuss recent Czech legislative changes around medical psilocybin and their implications for ketamine-assisted psychotherapy and future psychedelic medicines. Key implementation issues include professional roles, training standards, reimbursement, domestic production of psilocybin, and the development of multidisciplinary platforms for safe and accessible care.

Finally, the talk will situate current Czech work within a longer history of psychedelic research, including the legacy of Stanislav Grof, and reflect on how this history can intersect wtih contemporary regulation, clinical practice, and public-health approaches.